Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145119 | 0.92 | GRIN2B (0.43) | GRIN2BNAAAADAM17 | |
| SCHEMBL3400543 | 0.89 | GRIN2B (0.43) | GRIN2BNAAAADAM17S1PR5 | |
| SCHEMBL142211 | 0.89 | GRIN2B (0.43) | GRIN2BNAAAADAM17S1PR5 | |
| SCHEMBL141076 | 0.88 | GRIN2B (0.42) | GRIN2BNAAACHRM5CHRM1CHRM3 | |
| SCHEMBL16402974 | 0.83 | GRIN2B (0.36) | GRIN2B | |
| SCHEMBL6319951 | 0.83 | GRIN2B (0.39) | GRIN2B | |
| SCHEMBL144742 | 0.82 | GRIN2B (0.42) | GRIN2BNAAAADAM17 | |
| SCHEMBL143089 | 0.82 | GRIN2B (0.42) | GRIN2BNAAAADAM17TSHR | |
| SCHEMBL3402984 | 0.82 | GRIN2B (0.42) | GRIN2BNAAAADAM17TSHR | |
| SCHEMBL22776873 | 0.80 | ABCB1 (0.39) | GRIN2BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| EP-2250171-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | Achaogen, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009137130-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | RECQL, BLVRB, NQO2 | GRIN2B 2496/4885NAAA 679/4885CHRM5 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.